The purpose of this study is to investigate whether routine administration of fluoxetine 20mg
once daily in the 6 months initiated during the acute stroke improves the patient's
functional outcome.
EFFECTS is an investigator lead Sweden-based, multicenter, parallel group, double blind
placebo controlled trial with broad entry criteria and follow up at 6 and 12 months.
EFFECTS managed to recruit its anticipated numbers of 1,500 participants between 20th October
2014 and 28th June 2019. Data will be unblinded when the 6-months follow-up is completed, and
the primary outcome is due to report on May 2020.
Phase:
Phase 3
Details
Lead Sponsor:
Karolinska Institutet
Collaborators:
Hjärnfonden (The Swedish Brain foundation) Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse Stroke-Riksförbundet Swedish Heart Lung Foundation The Swedish Medical Association The Swedish Research Council